There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on United Therapeutics (UTHR – Research Report), Regeneron (REGN – Research Report) and Intuitive Surgical (ISRG – Research Report) with bullish sentiments.
United Therapeutics (UTHR)
In a report released yesterday, Tiago Fauth from Wells Fargo assigned a Buy rating to United Therapeutics, with a price target of $325.00. The company’s shares closed last Monday at $244.26.
According to TipRanks.com, Fauth has 0 stars on 0-5 stars ranking scale with an average return of
United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $289.44.
See the top stocks recommended by analysts >>
Regeneron (REGN)
In a report released yesterday, Mohit Bansal from Wells Fargo assigned a Buy rating to Regeneron, with a price target of $1050.00. The company’s shares closed last Monday at $961.09, close to its 52-week high of $998.33.
According to TipRanks.com, Bansal is a 4-star analyst with an average return of
Currently, the analyst consensus on Regeneron is a Strong Buy with an average price target of $1036.77, an 8.7% upside from current levels. In a report issued on March 11, Bernstein also initiated coverage with a Buy rating on the stock with a $1125.00 price target.
Intuitive Surgical (ISRG)
In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Intuitive Surgical, with a price target of $416.00. The company’s shares closed last Monday at $391.71, close to its 52-week high of $403.00.
According to TipRanks.com, Biegelsen is a 5-star analyst with an average return of
Currently, the analyst consensus on Intuitive Surgical is a Moderate Buy with an average price target of $414.56, implying a 5.3% upside from current levels. In a report issued on March 15, Stifel Nicolaus also maintained a Buy rating on the stock with a $420.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on UTHR:
- United Therapeutics Announces $1 Billion Stock Buyback Plan
- United Therapeutics price target raised to $325 from $309 at Wells Fargo
- United Therapeutics price target lowered to $262 from $264 at Ladenburg
- United Therapeutics Sues FDA Over Liquidia’s Drug Expansion
- United Therapeutics commences litigation with FDA on drug review process
